plerixafor has been researched along with diprotin a in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Broxmeyer, HE; Christopherson, KW; Hangoc, G; Mantel, CR | 1 |
Assmann, G; Brunner, S; Fischer, R; Franz, WM; Gröbner, M; Hacker, M; Huber, B; Krieg, L; Mueller-Hoecker, J; Rischpler, C; Theiss, HD; Vallaster, M; Vanchev, Y; Wollenweber, T; Zaruba, MM | 1 |
2 other study(ies) available for plerixafor and diprotin a
Article | Year |
---|---|
Modulation of hematopoietic stem cell homing and engraftment by CD26.
Topics: Animals; Benzylamines; Cell Cycle; Cell Movement; Cell Survival; Chemokine CXCL12; Chemokines, CXC; Chemotaxis; Cyclams; Dipeptidyl Peptidase 4; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Mice; Mice, Inbred C57BL; Oligopeptides; Receptors, CXCR4 | 2004 |
Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis.
Topics: Animals; Antigens, CD34; Benzylamines; Chemokine CXCL12; Cyclams; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Granulocyte Colony-Stimulating Factor; Heart Function Tests; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Leukocyte Common Antigens; Mice; Models, Biological; Myocardial Infarction; Neovascularization, Physiologic; Oligopeptides; Perfusion; Proto-Oncogene Proteins c-kit; Receptors, CXCR4; Stem Cell Transplantation; Survival Analysis | 2011 |